Name

Synergia Medical

Legal name

Synergia Medical SA

Website

https://synergia-medical.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Implantable Neuromodulation Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

Keywords

• Neuromodulation devices
• Vagus nerve stimulation
• Drug-resistant epilepsy
• Optoelectronic medical devices
• Implantable neurostimulators

Headquarters

HQ city

Mont-saint-guibert

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Pre-commercial medical device company developing the NAO.VNS neuromodulation device for drug-resistant epilepsy. Revenue expected from device sales upon regulatory approval (FDA, CE mark) through direct hospital/healthcare provider sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Synergia Medical develops the NAO.VNS™, a next-generation vagus nerve stimulation (VNS) implant for treating drug-resistant epilepsy. The device is built on a proprietary optoelectronic platform (NAO) that replaces metal components with quartz, polymer optical fibers, and miniaturized photovoltaic cells to deliver full MRI compatibility, EMI immunity, extended battery life (~1 minute daily recharge, 15-year lifetime), and enhanced cybersecurity through closed-loop optical communication. The product is currently investigational and in first-in-human clinical trials (AURORA study) in Belgium, with pivotal FDA and CE-mark trials planned.

Product overview

Synergia Medical offers a single unified neuromodulation product: the NAO.VNS™ system. This next-generation vagus nerve stimulation device is built on the proprietary NAO (Neuromodulation Advanced with Optoelectronics) technology platform, which replaces traditional metal components with biocompatible materials (quartz, polymer optical fibers, miniaturized photovoltaic cells) to deliver therapy with full MRI compatibility, EMI immunity, extended battery life (15 years with 1-minute daily recharge), and enhanced cybersecurity through optical communication. The device is designed to reduce epileptic seizures in patients with drug-resistant epilepsy.

Differentiator

Problem solved

Functional benefit

Products and services

• NAO.VNS™ An investigational, next-generation vagus nerve stimulation implant for adults and children with drug-resistant epilepsy who have failed at least two anti-epileptic drugs. Built on the proprietary NAO (Neuromodulation Advanced with Optoelectronics) platform, it replaces metal components with quartz encapsulation, polymer optical fibers, and miniaturized photovoltaic cells to provide full MRI compatibility, EMI immunity, ~1-minute daily recharge with an expected 15-year battery life, and closed-loop optical communication for cybersecurity.

Quantifiable outcome

• 40% responder rate (≥50% seizure reduction) at 3 months post-implantation
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered core.

• UZ Gent (Ghent University Hospital)coreStrategic or Co-development PartnerClinical trial partner for AURORA First-In-Human study. Dr. Frank Dewael performed implantations and Prof. Dr. Kristl Vonck serves as Principal Investigator. Prof. Vonck is also a Medical Advisor to Synergia Medical and Head of Department at the Reference Center for Refractory Epilepsy.
• Cliniques universitaires Saint-LuccoreStrategic or Co-development PartnerClinical trial partner for AURORA First-In-Human study. Dr. Herbert Rooijakkers performed implantations and Dr. Riëm El Tahry serves as Principal Investigator. Jacques van Rijckevorsel is President of the Board at Cliniques Universitaires Saint-Luc.
• Pascal DoguetcoreOthersCo-founder of Synergia Medical and inventor of the NAO.VNS technology.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Abbott: Abbott (via its former St. Jude Medical business) is a major player in DBS and other neuromodulation, and its board presence at Synergia underscores direct overlap. It is a broad incumbent with overlapping but broader neurostim capabilities than Synergia's VNS-only focus.
• Medtronic: Medtronic operates one of the broadest implantable neurostimulation portfolios (DBS for movement disorders, spinal cord stimulation, and related devices). It is a broad incumbent that competes with Synergia for hospital budgets and physician mindshare in the neurostim category.
• Boston Scientific: Boston Scientific markets DBS and spinal cord stimulation systems and has historical VNS exposure through prior ownership. It is a broad incumbent across neurostimulation that competes for the same specialist implanting physicians and hospital purchasing committees.

Direct peers

• LivaNova: LivaNova markets Vagus Nerve Stimulation (VNS) Therapy, the incumbent standard of care for drug-resistant epilepsy — the same indication Synergia's NAO.VNS targets. It is the most direct peer in product, indication, customer, and business model.
• NeuroPace: NeuroPace develops the RNS System, a closed-loop responsive neurostimulator for drug-resistant epilepsy. It competes head-to-head with NAO.VNS for the same patient population, implanting physicians, and epilepsy centers.

Emerging players

• Saluda Medical: Saluda Medical develops the Evoke closed-loop spinal cord stimulation system. It is comparable as a next-generation implantable neurostimulator focused on improved measurement and closed-loop therapy, sharing a similar technology-driven differentiation narrative.
• Inspire Medical Systems: Inspire is an established implantable neurostimulator company (hypoglossal nerve stimulation for obstructive sleep apnea). While the indication differs, it is a relevant comparable for an emerging neurostim company scaling commercial operations and reimbursement.
• Mainstay Medical: Mainstay Medical develops ReActiv8, an implantable restorative neurostimulator for chronic mechanical low back pain. It is comparable to Synergia as a clinical-stage-to-commercial-stage implantable neurostim company pursuing differentiated mechanism and reimbursement pathways.
• electroCore: electroCore develops non-invasive vagus nerve stimulation (nVNS, gammaCore) for indications including epilepsy and headache. It targets the same vagus nerve pathway as Synergia, with a non-invasive delivery model as a competing approach.

Others

• MicroPort Scientific / NeuroTech: MicroPort and adjacent neurotech subsidiaries market DBS and other implantable neurostim devices in global markets, including Europe. They are adjacent players in the broader implantable neuromodulation category relevant to Synergia's commercial benchmarking.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/synergia-medical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synergia Medical